Location: Animal Biosciences & Biotechnology Laboratory
Project Number: 8042-32000-107-030-T
Project Type: Trust Fund Cooperative Agreement
Start Date: Oct 1, 2017
End Date: Dec 30, 2019
Objective:
Investigate effects of commercial Seppic oral adjuvants on recombinant protein vaccination against avian coccidiosis. Underling protective mechanisms that are associated with recombinant vaccination with oral adjuvants will be investigated.
Approach:
ARS will test vaccine efficacy of recombinant coccidian proteins that ARS produced with commercially available Seppic adjuvants using ARS-established in vivo coccidiosis disease challenge model. Challenge model will be evaluated using established clinical criteria for coccidiosis infection.
